10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
Following consultation with members – and heeding the concerns of the Consumers Health Forum (CHF) and patient groups – pharma trade group Medicines Australia reiterates its call to have finalization of the new National Medicines Policy (NMP) delayed until after the federal election. 10 February 2022
The US Food and Drug Administration said yesterday that it has taken new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction. 10 February 2022
The US regulator has accepted for Priority Review a bid to broaden the label for the antibody Dupixent (dupilumab) in moderate-to-severe atopic dermatitis. 10 February 2022
Shares of Danish CNS specialist Lundbeck closed down 7.4% at 148.55 kroner after it reported financial results for the fourth quarter and full year 2021. 10 February 2022
GlobalData has identified that drug pricing pressures are seen as the major hindrance to the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus. 10 February 2022
German infectious disease drug developer AiCuris and Netherlands-based biotech Hybridize Therapeutics today announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. 9 February 2022
US biotech firm Ventus Therapeutics, which is developing small molecule therapeutics across a broad range of disease indications, announced today the closing of a $140 million Series C financing. 9 February 2022
UK-headquartered pharma services and products company Clinigen Group announced it has signed a distribution agreement, with USA-based Deciphera Pharmaceuticals for the supply and distribution of Qinlock (ripretinib) into multiple countries across the globe. 9 February 2022
Presenting an upbeat set of financial results, the company’s first since refusing a £50 billion ($68.4 billion) offer for its consumer health unit, GlaxoSmithKline said it took in £34.1 billion in 2021, £9.5 billion of which came in the final quarter. 9 February 2022
Indian drugmaker Lupin Limited today announced that it has entered into a distribution agreement with Slovenia-based Medis Pharmaceutical for Lupin’s orphan drug NaMuscla (mexiletine). 9 February 2022
German biopharmaceutical contract development and manufacturing organization (CDMO AGC Biologics has expanded its partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, at the company’s Heidelberg facility. 9 February 2022
French biotech MaaT Pharma has entered into a partnership agreement with contract development and manufacturing organization (CDMO) Skyepharma to build what to date will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. 9 February 2022
Since the early days of the pandemic, a number of developers have pursued the concept of using a nasal spray to administer anti-virals for treatment and prevention of coronavirus. 9 February 2022
US neurological diseases specialist Ovid Therapeutics and AI-powered drug discovery company Healx have announced a strategic partnership. 8 February 2022
US cancer-focussed firm Karyopharm Therapeutics saw its shares plunge nearly 23% to $7.93 by mid-morning, despite the company releasing a bullish statement on a new trial of its already marketed drug Nexpovio/Xpovio (selinexor) as a treatment for endometrial cancer. 8 February 2022
New Jersey-based Outlook Therapeutics, a biopharma company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications, has announced the appointment of Joel Prieve as senior vice president, Commercial Operations. 8 February 2022
US biotech giant Amgen late yesterday announced financial results for the fourth quarter and full year 2021, with earnings coming in ahead of analysts’ forecasts. 8 February 2022
US pharma giant Pfizer’s chairman and chief executive Albert Bourla was able to bask in the glory of a record-breaking year when he presented the group’s fourth-quarter and annual financial results for 2021 on Tuesday. 8 February 2022
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024